DE69619250D1 - Verbesserte arzneimittel mit einem ionenaustauschharz - Google Patents

Verbesserte arzneimittel mit einem ionenaustauschharz

Info

Publication number
DE69619250D1
DE69619250D1 DE69619250T DE69619250T DE69619250D1 DE 69619250 D1 DE69619250 D1 DE 69619250D1 DE 69619250 T DE69619250 T DE 69619250T DE 69619250 T DE69619250 T DE 69619250T DE 69619250 D1 DE69619250 D1 DE 69619250D1
Authority
DE
Germany
Prior art keywords
ion exchange
exchange resin
pct
date
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69619250T
Other languages
English (en)
Other versions
DE69619250T2 (de
Inventor
Therese Malkowska
Allan Prater
Thomas Leslie
Adrian Brown
John Knott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of DE69619250D1 publication Critical patent/DE69619250D1/de
Application granted granted Critical
Publication of DE69619250T2 publication Critical patent/DE69619250T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
DE69619250T 1995-09-01 1996-09-02 Verbesserte arzneimittel mit einem ionenaustauschharz Expired - Lifetime DE69619250T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9517883.6A GB9517883D0 (en) 1995-09-01 1995-09-01 Improved pharmaceutical ion exchange resin composition
PCT/GB1996/002156 WO1997009036A2 (en) 1995-09-01 1996-09-02 Improved pharmaceutical ion exchange resin composition

Publications (2)

Publication Number Publication Date
DE69619250D1 true DE69619250D1 (de) 2002-03-21
DE69619250T2 DE69619250T2 (de) 2002-08-14

Family

ID=10780065

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69619250T Expired - Lifetime DE69619250T2 (de) 1995-09-01 1996-09-02 Verbesserte arzneimittel mit einem ionenaustauschharz

Country Status (9)

Country Link
US (1) US6077532A (de)
EP (1) EP0847273B1 (de)
AT (1) ATE213152T1 (de)
AU (1) AU6834796A (de)
DE (1) DE69619250T2 (de)
ES (1) ES2170258T3 (de)
GB (1) GB9517883D0 (de)
PT (1) PT847273E (de)
WO (1) WO1997009036A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2288876A1 (en) * 1997-05-06 1998-11-12 Xiao Yu Wu Drug delivery system
SI1685839T1 (sl) 1997-12-22 2013-08-30 Euro-Celtique S.A. Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista
TR200001828T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
US6221308B1 (en) * 1999-04-20 2001-04-24 Corning Incorporated Method of making fired bodies
NZ520554A (en) 2000-02-08 2005-08-26 Euro Celtique S Tamper-resistant oral opioid agonist formulations
CN1396829A (zh) * 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
DK1416842T3 (da) * 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
DE60232417D1 (de) 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
KR20040098050A (ko) 2002-04-05 2004-11-18 유로-셀띠끄 소시에떼 아노님 옥시코돈 및 날록손을 포함하는 약제학적 제제
PT1551372T (pt) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
EP1667658A2 (de) * 2003-09-03 2006-06-14 Mallinckrodt Inc. Granulatförmiges präparat mit verzögerter freisetzung und seine herstellung
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20070232695A1 (en) * 2004-01-28 2007-10-04 Collegium Pharmaceutical, Inc. Gelled Periodontal Anesthetic Preparation
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
EP1846040A2 (de) * 2005-01-28 2007-10-24 Collegium Pharmaceutical, Inc. Nicht ionische und nicht wässrige transportelemente zur topischen und oralen verabreichung träger-komplexierter wirkstoffe
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
EP1834634A3 (de) * 2006-03-08 2007-10-03 Rentschler Pharma GmbH Aus mehrfacher Einzeleinheiten bestehender pharmazeutische Zusammensetzung
US8158156B2 (en) 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
EP2120945A1 (de) * 2007-02-28 2009-11-25 Collegium Pharmaceutical, Inc. Antihistamin-kombination
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2405915B1 (de) 2009-03-10 2018-10-24 Euro-Celtique S.A. Unmittelbare freisetzung pharmazeutischer zusammensetzungen mit oxycodon und naloxon
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627583A (en) * 1969-04-29 1971-12-14 Sucrest Corp Direct compression vehicles
EP0200252B1 (de) * 1985-05-02 1999-03-10 Yamanouchi Europe B.V. Trimethoprim und ein Sulfonamid enthaltende Tabletten
EP0328877A1 (de) * 1988-02-18 1989-08-23 Oerlikon-Contraves AG Geschoss mit Splittermantel
FI81004C (fi) * 1988-02-25 1990-09-10 Suomen Sokeri Oy Binde- och utspaedningsmedel pao basis av xylitol och foerfarande foer dess framstaellning.
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
HU206975B (en) * 1991-03-14 1993-03-01 Reanal Finomvegyszergyar Process for producing granulation and veterinary composition comprising water-soluble flumequine complex

Also Published As

Publication number Publication date
AU6834796A (en) 1997-03-27
DE69619250T2 (de) 2002-08-14
ES2170258T3 (es) 2002-08-01
WO1997009036A3 (en) 1997-04-24
PT847273E (pt) 2002-06-28
ATE213152T1 (de) 2002-02-15
WO1997009036A2 (en) 1997-03-13
GB9517883D0 (en) 1995-11-01
EP0847273B1 (de) 2002-02-13
EP0847273A2 (de) 1998-06-17
US6077532A (en) 2000-06-20

Similar Documents

Publication Publication Date Title
DE69619250D1 (de) Verbesserte arzneimittel mit einem ionenaustauschharz
AU5106996A (en) Process for producing active agent preparations in the form of a solid solution of the active agent in a polymer matrix and active agent preparations obtained thereby
NO971986D0 (no) Fremgangsmåte for fremstilling av små partikler
AU4453089A (en) Pharmaceutical ion exchange resin composition
MA26415A1 (fr) Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
AU7497294A (en) Substituted azadioxacycloalkenes and their use as fungicides
AU699480B2 (en) 2,2-Dichloroalkane carboxylic acids, processes for their production and pharmaceutical agents containing these
AU6870396A (en) New pyrimidone derivatives with antifungal activity
ATE259815T1 (de) Neue antagonistische verbindungen
NO973646L (no) Orale doseringsformer inneholdende et <beta>-laktam antibiotikum
CA2104917A1 (en) Use of Certain Anionic Surfactants to Enhance Antimicrobial Effectiveness of Ophthalmic Compositions
BR9408244A (pt) Derivados de azabiciclo[3.2.0]heptano N-substituídos
AU6518496A (en) Process for preparing optically active 1-(p-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisoquinoline
PT97541A (pt) Processo para a preparacao de indoles substituidos
TW357085B (en) Sustained release excipient
AU6742196A (en) Pesticidal indazole derivatives
HU9602041D0 (en) Oral dosage form containing colestipol as a carrier and acidic substances and a process for producing the same
AU7494496A (en) Production of a crystalline salt of amoxicillin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition